[1]黎百志,李晓慧,张爱文.外周血线粒体DNA、生长分化因子-15联合脑钠肽检测对心力衰竭的诊断价值[J].医学信息,2023,36(12):86-90124.[doi:10.3969/j.issn.1006-1959.2023.12.016]
　LI Bai-zhi,LI Xiao-hui,ZHANG Ai-wen.Diagnostic Value of Peripheral Blood Mitochondrial DNA, Growth Differentiation Factor-15 Combined with Brain Natriuretic Peptide in Patients with Heart Failure[J].Journal of Medical Information,2023,36(12):86-90124.[doi:10.3969/j.issn.1006-1959.2023.12.016]
点击复制

外周血线粒体DNA、生长分化因子-15联合脑钠肽检测对心力衰竭的诊断价值()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
36卷
期数:
2023年12期
页码:
86-90124
栏目:
论著
出版日期:
2023-06-15

文章信息/Info

Title:
Diagnostic Value of Peripheral Blood Mitochondrial DNA, Growth Differentiation Factor-15 Combined with Brain Natriuretic Peptide in Patients with Heart Failure
文章编号:
1006-1959（2023）12-0086-06
作者:
黎百志; 李晓慧; 张爱文
（承德医学院附属医院心脏内科，河北 承德 067000）
Author(s):
LI Bai-zhi; LI Xiao-hui; ZHANG Ai-wen
(Department of Cardiology, the Affiliated Hospital of Chengde Medical University,Chengde 067000,Hebei,China)
关键词:
线粒体DNA; 生长分化因子-15; 脑钠肽; 心力衰竭
Keywords:
Mitochondrial DNA; Growth differentiation factor-15; Brain natriuretic peptide; Heart failure
分类号:
R9541.6
DOI:
10.3969/j.issn.1006-1959.2023.12.016
文献标志码:
A
摘要:
目的 探讨外周血线粒体DNA（mtDNA）、生长分化因子-15（GDF-15）联合脑钠肽（BNP）检测对心力衰竭（HF）患者的诊断价值。方法 连续纳入2019年8月-2020年1月于承德医学院附属医院心脏内科住院的心力衰竭患者74例作为试验组。其中按照纽约心功能分级（NYHA），NYHAⅡ级患者10例，NYHAⅢ级患者14例，NYHAⅣ级患者50例，同期住院心功能正常患者75例作为对照组。收集入选对象外周血标本，应用实时定量RT-PCR检测入选对象外周血mtDNA含量，应用ELISA法测量入选对象外周血GDF-15的含量，收集电化学发光法检测的BNP含量及一般临床资料，建立基线数据库。结果 多因素回归分析显示，外周血GDF-15升高、mtDNA水平下降是心力衰竭的独立危险因素。与对照组比较，心力衰竭组外周血mtDNA的含量较低，GDF-15、BNP的水平较高，差异有统计学意义（P＜0.05）；ROC曲线分析显示，mtDNA、GDF-15、BNP、的曲线下面积分别是0.784、0.803、0.964，联合三者的曲线下面积是0.979（P＜0.05）。结论 心力衰竭患者外周血中mtDNA表达降低，GDF-15、BNP水平升高，BNP联合mtDNA、GDF-15可提高对心力衰竭的诊断能力。
Abstract:
Objective To explore the diagnostic value of peripheral blood mitochondrial DNA (mtDNA), growth differentiation factor-15 (GDF-15) combined with brain natriuretic peptide (BNP) in patients with heart failure (HF).Methods A total of 74 patients with heart failure who were hospitalized in the Department of Cardiology, Affiliated Hospital of Chengde Medical University from August 2019 to January 2020 were continuously included as the experimental group. According to the New York Heart Association(NYHA), there were 10 patients with NYHA Ⅱ, 14 patients with NYHA Ⅲ, 50 patients with NYHA Ⅳ, and 75 patients with normal heart function as control group. Peripheral blood samples were collected from the selected subjects. Real-time quantitative RT-PCR was used to detect the content of mtDNA in peripheral blood of the selected subjects. The content of GDF-15 in peripheral blood of the selected subjects was measured by ELISA. The content of BNP detected by electrochemiluminescence and general clinical data were collected to establish a baseline database.Results Multivariate regression analysis showed that elevated peripheral blood GDF-15 and decreased mtDNA levels were independent risk factors for heart failure. Compared with the control group, the content of mtDNA in peripheral blood of the heart failure group was lower, and the levels of GDF-15 and BNP were higher (P<0.05). ROC curve analysis showed that the area under the curve of mtDNA, GDF-15, BNP was 0.784, 0.803, 0.964, respectively, and the area under the curve of the combination of the three was 0.979 (P<0.05).Conclusion The expression of mtDNA in peripheral blood of patients with heart failure is decreased, and the levels of GDF-15 and BNP are increased. BNP combined with mtDNA and GDF-15 can improve the diagnostic ability of heart failure.

参考文献/References:

[1]Callan PD,Clark AL.Heart failure -what’s new and what’s changed?[J].Clin Med (Lond),2017,17(4):341-346.[2]Benjamin EJ,Blaha MJ,Chiuve SE,et al.American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart Disease and Stroke Statistics-2017 Update: A Report From the American HeartAssociation[J].Circulation,2017,135(10):e146-e603.[3]王华,梁延春.中国心力衰竭诊断和治疗指南2018[J].中华心血管病杂志,2018,46(10):760-789.[4]Huang CK,Kafert-Kasting S,Thum T.Preclinical and Clinical Development of Noncoding RNA Therapeutics for Cardiovascular Disease[J].Circ Res,2020,126(5):663-678.[5]Kuznetsova T,Knez J.Peripheral Blood Mitochondrial DNA and Myocardial Function[J].Adv Exp Med Biol,2017,982:347-358.[6]Ponikowski P,Voors AA,Anker SD,et al.2016 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure[J].Kardiol Pol,2016,74(10):1037-1147.[7]Wang H,Chen Q,Li Y,et al.Prognostic value of growth differentiation factor-15 in Chinese patients with heart failure: A prospective observational study[J].Cardiol J,2018,25(2):245-253.[8]Knez J,Lakota K,Bo?觩ic N,et al.Correlation Between Mitochondrial DNA Content Measured in Myocardium and Peripheral Blood of Patients with Non-Ischemic Heart Failure[J].Genet Test Mol Biomarkers,2017,21(12):736-741.[9]Wollert KC,Kempf T,Wallentin L.Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease[J].Clin Chem,2017,63(1):140-151.[10]George M,Jena A,Srivatsan V,et al.GDF 15--A Novel Biomarker in the Offing for Heart Failure[J].Curr Cardiol Rev,2016,12(1):37-46.[11]Zelniker TA,Jarolim P,Silverman MG,et al.Prognostic role of GDF-15 across the spectrum of clinical risk in patients with NSTE-ACS[J].Clin Chem Lab Med,2019,57(7):1084-1092.[12]Zeng X,Li L,Wen H,et al.Growth-differentiation factor 15 as a predictor of mortality in patients with heart failure: a meta-analysis[J].Cardiovasc Med (Hagerstown),2017,18(2):53-59.[13]Wang H,Chen Q,Li Y,et al.Prognostic value of growth differentiation factor-15 in Chinese patients with heart failure: A prospective observational study[J].Cardiol,2018,25(2):245-253.[14]Li J,Cui Y,Huang A,et al.Additional Diagnostic Value of Growth Differentiation Factor-15 (GDF-15) to N-Terminal B-Type Natriuretic Peptide (NT-proBNP) in Patients with Different Stages of Heart Failure[J].Med Sci Monit,2018,24:4992-4999.[15]Hao J,Cheang I,Zhang L,et al.Growth differentiation factor-15 combined with N-terminal prohormone of brain natriuretic peptide increase 1-year prognosis prediction value for patients with acute heart failure: a prospective cohort study[J].Chin Med J (Engl),2019,132(19):2278-2285.[16]Hong YS,Longchamps RJ,Zhao D,et al.Mitochondrial DNA Copy Number and Incident Heart Failure: The Atherosclerosis Risk in Communities (ARIC) Study[J].Circulation,2020,141(22):1823-1825.[17]Huang J,Tan L,Shen R,et al.Decreased Peripheral Mitochondrial DNA Copy Number is Associated with the Risk of Heart Failure and Long-term Outcomes[J].Medicine (Baltimore),2016,95(15):e3323.

相似文献/References:

[1]黎百志,李晓慧,张爱文.心力衰竭新型生物标志物的研究[J].医学信息,2021,34(14):28.[doi:10.3969/j.issn.1006-1959.2021.14.008]
　LI Bai-zhi,LI Xiao-hui,ZHANG Ai-wen.Research on New Biomarkers of Heart Failure[J].Journal of Medical Information,2021,34(12):28.[doi:10.3969/j.issn.1006-1959.2021.14.008]

更新日期/Last Update: 1900-01-01